Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis

Inflammation Research

Volumn 65, Issue 2, 2016, Pages 125-132

  Dixit, Puneet ^a   Garg, Ravindra Kumar ^a   Malhotra, Hardeep Singh ^a   Jain, Amita ^a   Verma, Rajesh ^a   Sharma, Praveen Kumar ^a   Kumar, Neeraj ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Cerebrospinal fluid; Cytokines; Interleukin; Longitudinally extensive transverse myelitis; Matrix metalloproteinases

Indexed keywords

CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METHYLPREDNISOLONE; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ACUTE TRANSVERSE MYELITIS; ADULT; ARTICLE; BARTHEL INDEX; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELITIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARAPLEGIA; PROTEIN CEREBROSPINAL FLUID LEVEL; QUADRIPLEGIA; ADOLESCENT; CASE CONTROL STUDY; INDIA; MYELITIS, TRANSVERSE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INDIA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYELITIS, TRANSVERSE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84955199679     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0896-8     Document Type: Article

References (18)

1. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59:499–505.
2. Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist. 2005;11:2–18.
3. Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483–99.
4. Pandit L. Transverse myelitis spectrum disorders. Neurol India. 2009;57:126–33.
5. Cree BAC. Acute inflammatory myelopathies. Handb Clin Neurol. 2014;122:613–67.
6. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16:1443–52.
7. Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, Santiago-Raber ML, Hochstrasser DF, Lalive PH. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE. 2013;8:e72399.
8. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994;4:145–56.
9. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279–91.
10. Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H, Abe M, Koga M, Kanda T. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2014;85:419–30.
11. Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006;12:169–73.
12. Hofer MJ, Campbell IL. Immunoinflammatory diseases of the central nervous system—the tale of two cytokines. Br J Pharmacol. 2015. doi:10.1111/bph.13175.
13. Linhares UC, Schiavoni PB, Barros PO, Kasahara TM, Teixeira B, Ferreira TB, Alvarenga R, Hygino J, Vieira MM, Bittencourt VC, Andrade RM, Andrade AF, Bento CA. The ex vivo production of IL-6 and IL-21 by CD4 + T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013;33:179–89.
14. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Investig. 2005;115:2731–41.
15. Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302–6.
16. Hosokawa T, Nakajima H, Doi Y, Sugino M, Kimura F, Hanafusa T, Takahashi T. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood–brain barrier. J Neuroimmunol. 2011;236:81–6.
17. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic’s neuromyelitis optica. Brain. 2001;124:493–8.
18. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008;196:124–32.